- The company also participated in the H.C. Wainwright BioConnect Conference earlier in January
- CNS Pharmaceuticals recently received approval from swissethics for a pivotal Berubicin and GBM clinical trial
- The five-year survival rate for GBM is only 6.8%, with the average patient population surviving 12 to 18 months after diagnosis
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, recently participated in the Virtual Investor 2022 Top Picks Conference. During the event, CEO John Climaco provided a corporate presentation and then participated in a moderated questions and answer session.
In addition to being moderated, investors and interested parties were given the opportunity to submit questions to Mr. Climaco during the live event. The conference also accepted pre-submitted questions before the event, and the company answered as many as possible before their allotted time was up.
A live video webcast of the event can be found the Events page of CNS Pharmaceuticals’ website (https://ibn.fm/Vk4cN). This webcast, featuring CNS Pharmaceuticals and Mr. Climaco, will be available for playback for one year. Earlier in January, the company participated in the H.C. Wainwright BioConnect Conference, held virtually, with Mr. Climaco also speaking.
CNS Pharmaceuticals’ lead drug candidate is Berubicin, a novel anthracycline and the first in its drug class to appear to cross the blood-brain barrier. The company is currently developing treatments using Berubicin for serious brain and central nervous system oncology indications, including glioblastoma multiforme (“GBM”), an aggressive and incurable form of cancer in the brain.
More than 13,000 Americans were expected to receive a diagnosis of GBM in 2020, with the cancer accounting for 48% of all primary, malignant brain tumors. In terms of survival rates, the five-year survival rate for GBM patients is only 6.8%. The average length of survival from diagnosis is 12 to 18 months (https://ibn.fm/oX7H3).
CNS Pharmaceuticals holds the worldwide exclusive license to Berubicin’s chemical compound. The company acquired all requisite data from Reata Pharmaceuticals Inc. relating to Phase I trials of Berubicin in malignant brain tumors. Roughly 44% of patients participating in this trial 14 years ago experienced significant improvement clinically. CNS Pharmaceuticals intends to explore Berubicin in other potential treatments for indications other than central nervous system cancers, including pancreatic and ovarian cancers and lymphoma.
The company is also developing its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecular agents, which are believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 have demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is even evaluating the use of WP1244 in the treatment of brain cancers, pancreatic and ovarian cancer, and lymphoma.
To close out 2021, CNS Pharmaceuticals received approval from swissethics, the umbrella organization of the cantonal Ethics Committee in Switzerland, for a pivotal Berubicin study for GBM (https://ibn.fm/JduRf). “Receiving approval from swissethics is a significant milestone for the company. Our stated goal is, and always has been, to see Berubicin approved for the treatment of glioblastoma, and this means globally,” Mr. Climaco said. “This terrible disease does not discriminate on the basis of geography or anything else: Patients in Europe are as desperate as patients in the United States, and treating patients is not only why we do what we do, but how we do it as well.”
For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.